Clinical Trial Update: Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating adoptive T cell therapy after a HER2-pulsed dendritic cell vaccine, in combination with pepinemab and trastuzumab, for metasta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HER2-pulsed dendritic cell vaccine
• Pepinemab (pepinemab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: HER2-positive Breast Cancer | Phase 1 | Status: RECRUITING